Growth (Tamro Group)

The main activity of ROSTA CJSC is wholesale sale of medicines, medical products and parapharmaceutical products to pharmacies and medical institutions. The company is a supplier of more than 15,000 pharmacies and treatment and prevention facilities. In Russia, the company is represented by 28 branches and 14 sales missions. According to the results of 2014, it is one of the three largest distributors in terms of share in the market for direct supplies of medicines.

History

2021: "Sber Eapteka" occupied the area of ​ ​ the bankrupt pharmaceutical distributor "Growth"

As it became known at the end of March 2021, the Sber Eapteka company occupied the area of ​ ​ the bankrupt pharmaceutical distributor Rosta. We are talking about an industrial site in the Konnaya Lakhta industrial park, which the Sbera subsidiary will use as a distribution center. The financial terms of the transaction are not disclosed.

This is the only ready-made automated pharmaceutical warehouse that can be quickly commissioned, Anton Buzdalin, general director of Sber Eapteki, told Kommersant. According to him, the distribution center will serve the needs of its own and partner pharmacies of the service in St. Petersburg and the Leningrad region. As of the end of March 2021, 95 points in the region were connected to Eaptec.

Sberbank explained that leasing space will increase the commercial attractiveness of the object for subsequent sale.

"Sber Eapteka" occupied the area of ​ ​ the bankrupt pharmaceutical company "Growth"

In January 2021, Sberbank put up for auction a pharmaceutical holding plant in St. Petersburg with a land plot of 2.3 hectares, as well as claims for 5.5 billion rubles to Rosta JSC, collateral for which is a warehouse in Novosibirsk (11.5 thousand square meters). The initial value of this property is 2.6 billion rubles.

The head of the JLL office in St. Petersburg, Andrei Amosov, believes that the Rosta complex can cost 600 million rubles. Bright Rich partner|CORFAC International Viktor Zaglumin estimates its cost at 39-41 thousand rubles per square meter excluding VAT (700-740 million rubles). First of all, the object will be interesting to pharmaceutical companies, he notes.

The main interests will rather be pharmaceutical companies that need production and their own office, agrees Colliers Olga Urevich, senior consultant at the Department of Warehouse, Industrial Real Estate and Land.^[1]

2019: Moscow Region Arbitration Court declares bankruptcy

On February 14, 2019, it became known that having declared the Rosta pharmaceutical distributor bankrupt, the Moscow Region Arbitration Court opened bankruptcy proceedings against the company for 6 months.

Dmitry Pakhtusov, who is a member of the "Self-Regulatory Organization of Arbitration Managers of the North-West" (St. Petersburg), was appointed bankruptcy trustee.

The procedure for declaring Rosta JSC insolvent was initiated by a certain Pavel Kostenko.

Among the main creditors of Rostov is Sberbank with a claim amount of more than 4 billion rubles, Bayer (more than 1.8 billion rubles), Berlin-Chemie (more than 720 million rubles) and Johnson & Johnson (more than 600 million rubles). The general requirements at the time of the meeting of creditors exceeded 25.6 billion^[2]

2017: The beginning of difficult times

The problems of the Rosta group began in 2017 after rumors appeared about the sale of distribution and retail businesses "36.6." The company tried to resolve the situation. So, in July 2017, Rosta sold Erkafarm Group of Companies a retail business - the combined pharmacy chain Rainbow - First Aid - Ladushka (1.18 thousand pharmacies), which had a turnover of 20.2 billion rubles in 2016. However, all the same, the company's net loss for 2017 year amounted to 13.9 billion rubles.

Rosta in 2017 pledged the property of the St. Petersburg pharmacy plant Rainbow Production, which was part of the group of the same name, Sberbank and Nizhfarm. But this did not help settle debts.

Rosta JSC was previously one of the top three in terms of retail sales of medicines in Russia, occupying 12% of the market.

2008

In 2008, the company in Russia had 28 branches and 15 representative offices.

2007: Turnover exceeded $1 billion

In 2007, the turnover of the pharmaceutical group "GROWTH" exceeded 1 billion US dollars. Together with an increase in sales, mainly due to participation in budget programs, ROSTA was at the center of the so-called financial crisis of the UFO system. The essence of the crisis was that the needs for drug supply of the program were significantly higher than the volume of state funding. On the other hand, the Accounts Chamber of the Russian Federation revealed massive cases of the supply of medicines without appropriate applications or in excess of the declared amount, as a result of which, according to experts of the Accounts Chamber, the volume of medicines was significantly overstated.

As a result, distributors (participants in the UFO program) delivered more drugs than the state was able to pay, and distributors were unable to pay their suppliers and other participants in the program in a timely manner. For example, only to pharmacies of the Altai Territory, the debt of ZAO ROSTA for 2006 - 2007 amounted to more than 61 million rubles.

2006: Creation of a retail chain under the brand "Rainbow"

In 2006, ROSTA created an affiliated retail chain under the Rainbow brand. There are significant changes in the structure of the owners of the company. The Finnish company Tamro Group becomes the owner of a 42.5% stake in ZAO ROSTA. According to the DSM Group, in 2006, ROSTA was able to significantly increase sales, its market share was 8%, which corresponds to 3rd place in the ranking of pharmaceutical distributors in Russia.

2005

In the same 2005, when ROSTA became a participant in the Federal Program of UFO (Additional Drug Support), it was recognized as the responsible supplier of medicines in 24 constituent entities of the Russian Federation. The company's rating on sales volumes rose to third place in the total ranking of pharmaceutical distributors.

The expert assessment of the company's share in the country's pharmaceutical market in 2005 amounted to 3.74%.

2004

In 2004, the company "ROSTA" in terms of sales was confidently fixed in 4th place.

2003

The activities of ROSTA in 2003 were evaluated in different ways by various leading analytical centers in the pharmaceutical industry. So, for example, according to the Pharmaceutical Bulletin publishing house, ROSTA, in terms of sales, already in 2003 took 4th place in the list of the largest pharmaceutical distributors in Russia.

And according to the analytical company RMBC (Remedium Group of Companies), ROSTA was not even included in the list of the five largest pharmaceutical distributors.

2002: Foundation

ZAO ROSTA was founded in 2002 as a result of the merger of several pharmaceutical companies: the regional distributor Farm Tamda 77 St. Petersburg (), the national distributor of medicines Rossib Pharmacy Novosibirsk () and the regional distributor ArthroMed (Samara). The Finnish concern Tamro, a pharmaceutical distributor in Northern, became the European partner of ROSTA. To Europe The creation of the company "ROSTA," according to the Institute of Public, was health care called the 2002 event in the pharmaceutical market. At the Russia time of the creation of ZAO ROSTA, the consolidated sales volume of the combined companies amounted to $184.7 million.

Notes